Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ALZN Alzamend Neuro Inc

-0.0357 (-3.34%)
Last Updated: 12:32:37
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Alzamend Neuro Inc ALZN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0357 -3.34% 1.0343 12:32:37
Open Price Low Price High Price Close Price Prev Close
1.05 1.00 1.05 1.07
more quote information »

Recent News

Date Time Source Heading
12/11/20239:23IHNWFeaturedAether Global Innovations Corp. Announces Non-Brokered Private Placement
12/11/202308:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
11/20/202308:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
11/16/202316:30EDGAR2Form 8-K - Current report
11/16/202308:00BWAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid..
11/13/202308:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
10/30/202316:30EDGAR2Form 8-K - Current report
10/30/202308:00BWAlzamend Neuro Announces Reverse Stock Split
10/23/202308:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
10/02/202308:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
9/29/202316:30EDGAR2Form 8-K - Current report
9/26/202318:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/22/202316:30EDGAR2Form 8-K - Current report
9/22/202308:00BWAlzamend Neuro Granted Extension by Nasdaq Panel to Regain..
9/13/202317:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
9/08/202317:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
9/08/202317:00EDGAR2Form 8-K - Current report
9/01/202316:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
8/30/202308:00BWAlzamend Neuro Submits IND Application for Phase IIA..
8/24/202316:30EDGAR2Form DEF 14A - Other definitive proxy statements
8/16/202316:30EDGAR2Form 8-K - Current report
8/11/202300:15EDGAR2Form EFFECT - Notice of Effectiveness
8/10/202316:30EDGAR2Form PRE 14A - Other preliminary proxy statements
8/07/202316:30EDGAR2Form 8-K - Current report
8/02/202316:31EDGAR2Form S-3 - Registration statement under Securities Act of..
7/27/202316:56EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
6/22/202308:00BWAlzamend Neuro Announces Positive Phase IIA Clinical Trial..
6/13/202308:00BWAlzamend Neuro CEO Stephan Jackman to Participate on the..
4/04/202306:30BWAult Alliance Announces Alzamend Neuro Has Initiated Its..
4/03/202309:35BWKILL Alzamend Neuro Receives FDA “Study May Proceed” Letter..
4/03/202308:50BWAlzamend Neuro Announces the Initiation of a Phase I/IIA..
4/03/202308:00BWAlzamend Neuro Receives FDA “Study May Proceed” Letter for..
3/22/202308:00BWAlzamend Neuro Announces Completion of Clinical Portion of..
3/16/202308:00BWAlzamend Neuro Reports Third Fiscal Quarter Financial..
1/26/202308:00BWAlzamend Neuro to Present at Sequire Biotechnology..
1/04/202308:00BWAlzamend Neuro Partners With Biorasi to Conduct a..
12/28/202208:00BWAlzamend Neuro Partners With the Miller School of Medicine,..

Your Recent History

Delayed Upgrade Clock